Literature DB >> 33384960

Value of N1 Lymph Node Examination in the Prognosis of Patients With pT1-3N0M0 Non-Small Cell Lung Cancer.

Gaoxiang Wang1,2, Xianning Wu1,2, Xiaohui Sun1,2, Tian Li1,2, Meiqing Xu1,2, Liangdong Xu1,2, Mingran Xie1,2.   

Abstract

OBJECTIVE: This study aimed to analyze the relationship between the number of examined lymph nodes (ELNs) at the N1 station and the postoperative clinicopathological features and prognosis of patients with pT1-3N0M0 non-small cell lung cancer (NSCLC).
METHODS: The cut-off value of the number of ELNs at the N1 station was obtained using X-tile software analysis. Kaplan-Meier survival curve analysis and the Cox proportional hazard model were used to study the impact of the number of ELNs at the N1 station on the prognosis of postoperative patients with pT1-3N0M0 NSCLC.
RESULTS: The median survival time and 1-, 3- and 5-year survival rates of 0 ELNs at the N1 station were 28.0 months and 74.8%, 45.4%, and 21.2%, respectively. The median survival time and 1-, 3-, and 5-year survival rates of 1-4 ELNs at the N1 station were 45.0 months and 85.5%, 55.4%, and 39.1%, respectively. In the group with ≥ 5 ELNs at the N1 station, the median survival time and the 1-, 3- and 5-year survival rates were 59.0 months and 94.0%, 62.7%, and 48.2%, respectively. Both univariate and multivariate Cox regression analyses showed that the number of ELNs at the N1 station, T stage and operation type were independent factors affecting the prognosis of patients with pT1-3N0M0 NSCLC.
CONCLUSION: Increasing the number of ELNs at the N1 station is positively correlated with the long-term survival rate of patients with T1-3N0M0 NSCLC. At least 5 LNs at the N1 station should be examined in pathological examination.
Copyright © 2020 Wang, Wu, Sun, Li, Xu, Xu and Xie.

Entities:  

Keywords:  examined lymph node; non-small cell lung cancer; prognosis; surgery; survival

Year:  2020        PMID: 33384960      PMCID: PMC7770180          DOI: 10.3389/fonc.2020.603378

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  13 in total

Review 1.  Global patterns of cancer incidence and mortality rates and trends.

Authors:  Ahmedin Jemal; Melissa M Center; Carol DeSantis; Elizabeth M Ward
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Variability in defining T1N0 non-small cell lung cancer impacts locoregional failure and survival.

Authors:  Mert Saynak; Jessica Hubbs; Jiho Nam; Lawrence B Marks; Richard H Feins; Benjamin E Haithcock; Nirmal K Veeramachaneni
Journal:  Ann Thorac Surg       Date:  2010-11       Impact factor: 4.330

3.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

4.  Impact of Omission of Intrapulmonary Lymph Node Retrieval on Outcome Evaluation of Lung Cancer Patients Without Lymph Node Metastasis: A Propensity Score Matching Analysis.

Authors:  Xing Wang; Shi Yan; Chao Lv; Yuzhao Wang; Jia Wang; Shaolei Li; Lijian Zhang; Yue Yang; Nan Wu
Journal:  Clin Lung Cancer       Date:  2017-05-11       Impact factor: 4.785

5.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

6.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

7.  Survival and Resected Lymph Node Number During Sublobar Resection for N0 Non-Small Cell Lung Cancer 2 cm or Less.

Authors:  Hongdou Ding; Haifeng Wang; Li Xu; Nan Song; Gening Jiang
Journal:  Ann Thorac Surg       Date:  2019-01-22       Impact factor: 4.330

8.  Lymph Node Examination for Stage I Second Primary Lung Cancer Patients Who Received Second Surgical Treatment.

Authors:  Yan Chen; Jing Zhang; Linsong Chen; Jie Dai; Junjie Hu; Xinsheng Zhu; Kaixuan Zhang; Huansha Yu; Haiping Zhang; Ke Fei; Peng Zhang
Journal:  Ann Surg Oncol       Date:  2020-09-05       Impact factor: 5.344

9.  Prognostic relevance of regional lymph-node distribution in patients with N1-positive non-small cell lung cancer: A retrospective single-center analysis.

Authors:  F Eichhorn; L V Klotz; T Muley; S Kobinger; H Winter; M E Eichhorn
Journal:  Lung Cancer       Date:  2019-10-20       Impact factor: 5.705

10.  Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry.

Authors:  Wenhua Liang; Jiaxi He; Yaxing Shen; Jianfei Shen; Qihua He; Jianrong Zhang; Gening Jiang; Qun Wang; Lunxu Liu; Shugeng Gao; Deruo Liu; Zheng Wang; Zhihua Zhu; Calvin S H Ng; Chia-Chuan Liu; René Horsleben Petersen; Gaetano Rocco; Thomas D'Amico; Alessandro Brunelli; Haiquan Chen; Xiuyi Zhi; Bo Liu; Yixin Yang; Wensen Chen; Qian Zhou; Jianxing He
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

View more
  1 in total

1.  A standard for hilar and intrapulmonary lymph node dissection and pathological examination in early non-small cell lung cancer.

Authors:  Zhihua Zhu; Weijian Mei; Zhengbo Song; Wenjie Jiao; Qinghua Huang; Lianxin Zhu; Chaolun An; Jianguang Shi; Wenxian Wang; Guiping Yu; Pingli Sun; Yinbin Zhang; Jianfei Shen; Yong Song; Sebastien Gilbert; Kurt Ruetzler; Nestor R Villamizar; Chunwei Xu; Jun Qian; Wang Yao; Han Yang
Journal:  Transl Lung Cancer Res       Date:  2021-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.